Calidi Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Net Income	-29.22	-25.43	-10.93
Depreciation & Amortization	1.26	0.25	0.16
Share-Based Compensation	4.81	4.52	1.33
Other Operating Activities	-3.83	7.44	1.68
Operating Cash Flow	-26.98	-13.21	-7.77
Capital Expenditures	-0.59	-0.43	-0.21
Acquisitions	0.01	0	0
Other Investing Activities	0.1	-0.07	-0.01
Investing Cash Flow	-0.48	-0.49	-0.22
Share Issuance / Repurchase	3.04	0.11	0.14
Debt Issued / Paid	1.5	11.97	9.68
Other Financing Activities	24.5	-	-
Financing Cash Flow	29.04	12.09	9.81
Exchange Rate Effect	-0.01	-0.03	-0
Net Cash Flow	1.58	-1.65	1.82
Free Cash Flow	-27.57	-13.64	-7.98
Free Cash Flow Margin	-	-30315.56%	-1777.28%
Free Cash Flow Per Share	-1.63	-1.60	-0.40

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).